Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amino Acids to Prevent Postoperative AKI After Thoracic or Thoracoabdominal Aortic Surgery
jRCTs051210154Completed
- Sponsor
- Otsuka Holdings
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of amiparen in acute kidney failure (AKF), thoracic aortic aneurysm (TAA) and Thoracoabdominal aortic aneurysm (TAAA) (2 arms), sponsored by Otsuka Holdings. Primary endpoint: Acute kidney injury within 7 postoperative days. Started Feb 2022; status: completed.
02
Drugs
amiparen
03
Conditions
acute kidney failure (AKF)thoracic aortic aneurysm (TAA)Thoracoabdominal aortic aneurysm (TAAA)
Beyond the preview
Go deeper on jRCTs051210154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051210154.